a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

NCT04008888 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma
Plasma Cell Leukemia
Extramedullary Plasmacytoma
Loss of Chromosome 17p
t(14;16)
t(4;14)
T(14;20)
1Q21 Amplification
Complex Karyotype

Interventions

PROCEDURE: Allogeneic Hematopoietic Stem Cell Transplantation
PROCEDURE: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2
DRUG: Melphalan Given IV
DRUG: Fludarabine Injection
DRUG: PI and dexamethasone as maintenance therapy
DRUG: PI+IMids+Dexamethasone as Consolidated Chemotherapy

Sponsor

Institute of Hematology & Blood Diseases Hospital, China